Journal profile · Pharmacology & Pharmacy
Pharmacoepidemiology and Drug Safety
ISSN 1053-8569 · eISSN 1099-1557 · John Wiley and Sons Ltd · ENGLAND · Bimonthly · Founded 1992
Pharmacoepidemiology and Drug Safety: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.61; hybrid open access; APC about USD 4,650; median 178 days to acceptance (98 articles, last 24 months); community-reported acceptance: about 75%; 245 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Pharmacoepidemiology and Drug Safety is published by John Wiley and Sons Ltd and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacovigilance and Adverse Drug Reactions, Pharmaceutical Practices and Patient Outcomes and Pharmaceutical studies and practices, together about 36% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, post-marketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Brian L. StromPublisher website
Editorial board by country: 4 in mainland China (about 4%); most named United States 37, South Korea 11, Netherlands 11, Taiwan, China 5, United Kingdom 5 (96 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics18.5%
- Pharmaceutical Practices and Patient OutcomesMedicine9.2%
- Pharmaceutical studies and practicesMedicine8.2%
- Medication Adherence and ComplianceMedicine5.8%
- Advanced Causal Inference TechniquesMathematics5.6%
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance4.4%
- Pregnancy and Medication ImpactMedicine4.4%
- Drug-Induced Adverse ReactionsMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Public, Environmental & Occupational Health | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Public, Environmental & Occupational Health | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Public, Environmental & Occupational Health | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCASCurrent ContentsPublisher website
Other: EBSCO, ProQuest
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.61LetPub ·
- Impact factor (publisher)
- 2.6Publisher website ·
- Impact factor (publisher) 2025
- 2.6Publisher website ·
- CiteScore 2026-06
- 3.8LetPub ·
- CiteScore (publisher)
- 3.8Publisher website ·
- CiteScore (publisher) 2025
- 3.8Publisher website ·
- SJR 2026-06
- 1.04LetPub ·
- SNIP 2026-06
- 0.98LetPub ·
- h-index
- 85LetPub ·
- h-index
- 136OpenAlex ·
- i10-index
- 2,800OpenAlex ·
- 2-year mean citedness
- 2.23OpenAlex ·
- Self-citation rate
- 11.5%LetPub ·
- Share of gold OA articles
- 56.11%LetPub ·
Volume
- Articles per year
- 194LetPub ·
- Articles per year (publisher) 2025
- 207Publisher website ·
- Downloads per year (publisher) 2025
- 625,740Publisher website ·
Articles by year OpenAlex count · 6,210 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 204 | 138 | 31 |
| 2025 | 245 | 181 | 556 |
| 2024 | 216 | 162 | 893 |
| 2023 | 187 | 139 | 1,174 |
| 2022 | 200 | 115 | 2,205 |
| 2021 | 289 | 110 | 2,538 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
178 daysMedian, submission to acceptance · P25–P75 138 days – 244 days
- Acceptance to online
- median 17 days (99 articles)
- Submission to online
- median 206 days
- Sample
- 98 articles with submission and acceptance dates (479 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 75%LetPub ·
- Acceptance rate (publisher)
- 21%Publisher website ·
- Acceptance rate (publisher) 2025
- 21%Publisher website ·
- Submission to first decision
- 10 daysPublisher website ·
- Submission to first decision 2025
- 10 daysPublisher website ·
- Submission to acceptance 2025
- 197 daysPublisher website ·
- Acceptance to publication 2025
- 21 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,650 / EUR 3,990 / GBP 3,290 | — | — | |
| Publisher website | No APC | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Submission fee
- No submission fee
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Reference style
- AMA
- First submission
- Free format: the journal's layout is not required
- Graphical abstract
- Optional
Article types accepted15
- brief reportArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
- brief reportsBrief Reports Preliminary findings of research in progress or a case report of particular interest 1,500 limit, Structure: Purpose, Methods, Results, and Conclu…Length not stated
- case reportArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
- commentariesCommentaries Commentaries are evidence-based opinion pieces that cover a variety of topics of current interest in pharmacoepidemiology and pharmacovigilance, an…Length not stated
- commentaryArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
- letters to the editorArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
- meta-analysisArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
- opinionArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
- original articleArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
- original articlesOriginal Articles Reports of new research findings or conceptual analyses that make a significant contribution to knowledge 3,000 limit (excluding abstract, tab…Length not stated
- real-world data sources for pharmacoepidemiologic researchReal-World Data Sources for Pharmacoepidemiologic Research Dedicated to describing available real-world data sources for pharmacoepidemiologic studies.Length not stated
- reviewArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
- review articleArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
- review articlesReview Articles Critical reviews of the literature, including systematic reviews and meta-analyses. Hot topics, controversies, and pharmacoepidemiologic methods…Length not stated
- systematic reviewArticle Type Description Word Limit Abstract / Structure Other Requirements Original Articles Reports of new research findings or conceptual analyses that make …Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Data availability, License & copyright, Open access, Peer review, Preprints
- AI use Artificial Intelligence Generated Content
Generative Artificial Intelligence tools (GenAI) – such as ChatGPT and others based on large language models (LLMs) — cannot be considered capable of initiating an original piece of research without direction by human authors. They also cannot be accountable for a published work or for a research design, which is a generally held requirement of authorship, nor do they have legal standing or the ab…
Source ↗Publisher website ·- Authorship Authorship
No submission fees or page charges Model summary
The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:
Source ↗Publisher website ·- Data availability Data Sharing and Data Availability
Data sharing Model summary
Pharmacoepidemiology and Drug Safety strongly encourages authors to share the data and other documents supporting the results in the paper. Authors should consider providing a transparency statement in the manuscript following the structure suggested by Wang and Pottegård in Am J Epi (May 2023;kwae087). In brief, this statement explicitly states the level of transparency and data availability in t…
Source ↗Publisher website ·- License & copyright Reproduction of Copyright Material
If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is your responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ.
Source ↗Publisher website ·- Open access Open Access
PDS is a subscription journal that offers open access. You'll have the option to choose to make your article open access after acceptance, which will be subject to an APC. You can read more about APCs and whether you may be eligible for waivers or discounts, though your institution, funder, or country waiver.
Source ↗Publisher website ·- Peer review Submission and Peer Review Process
Single-blind peer review model Model summary
New submissions should be made via the Research Exchange submission portal https://authors.wiley.com/journal/PDS. You may check the status of your submission at any time byb logging on to submission.wiley.com and clicking the "My Submissions" button. For technical help with the submission system, please review our FAQs or contact submissionhelp@wiley.com.Equality, Diversity and Inclusivity Policy
Source ↗Publisher website ·- Preprints Preprint policy
Preprint policy Model summary
Pharmacoepidemiology & Drug Safety accepts articles previously published on preprint servers.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Wiley and Sons Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1992
- ISSN
- 1053-8569
- Electronic ISSN
- 1099-1557
- Society / sponsor
- International Society for Pharmacoepidemiology
- Latest issue on the website
- Volume 35, Issue 10 (October 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
FAQ
Frequently asked questions about Pharmacoepidemiology and Drug Safety
What CAS zone is Pharmacoepidemiology and Drug Safety in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmacoepidemiology and Drug Safety is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy / Public, Environmental & Occupational Health. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pharmacoepidemiology and Drug Safety?
The latest impact factor listed by LetPub is 2.61; CiteScore 3.8, h-index 136.
How long does peer review take at Pharmacoepidemiology and Drug Safety?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 178 days (interquartile range 138–244 days); authors report an average review time of about 3 months; the community-reported acceptance is “about 75%”; the journal's website gives an acceptance rate of 21% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Pharmacoepidemiology and Drug Safety?
According to the journal's author guidelines: Reference style: AMA; First submission: Free format: the journal's layout is not required; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Pharmacoepidemiology and Drug Safety based?
Of the 96 board members whose country the journal's board page names, 4 (about 4%) are in mainland China; the countries named most often are United States (37), South Korea (11) and Netherlands (11). Counted from the institutions listed on the board page; for reference only.
Which databases index Pharmacoepidemiology and Drug Safety?
According to LetPub and DOAJ records, Pharmacoepidemiology and Drug Safety is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Pharmacoepidemiology and Drug Safety open access, and what is the APC?
Pharmacoepidemiology and Drug Safety is a hybrid journal. For open-access publication: APC about USD 4,650.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .